Partner Article
Northwich-based Dechra Pharmaceuticals PLC remains ‘confident’
Competitor stock shortages in the US have meant strong revenues for Northwich-based Dechra Pharmaceuticals.
The manufacturer of veterinary products has reported that group revenue has increased in this quarter by 14.3% at constant exchange rates and 6% at actual exchange rates.
The European part of the business has seen revenues fall at actual exchange rates by 3.3% however sales were positively impacted by wholesalers buying in advance of Easter.
The company said: “ We remain on track to deliver our strategic milestones and further progress has been made in the period“
This was posted in Bdaily's Members' News section by Sophia Taha .
Our Partners
Taking advantage of the opportunities ahead
Accountability isn’t the enemy of empathy
Act now to avoid a last-minute tax scramble
How inner-city living can transform a city by the sea
Artificial intelligence's value is the time it gives back
Why we must break the magnetic pull of London
AI scepticism is healthy - inaction isn't
What does NPPF mean for planning gain and pricing?
What new NPPF rules mean for landowners
The hidden cost squeezing Britain's economy
Teesside deserves more than cashback devolution
Construction must be built on commercial discipline